Title: Trabedersen-Drug Development using phosphorothioate antisese platform

Abstract:

Using the PS antisense platform we were able to target TGF-β2 without impacting on the β1 and β3, thus avoided the toxicity related to β1 knockdown. OT-101 lifts the immunosuppression in the tumor allowing the body to recognize the tumor as foreign.  Once that is in place-     everything else is easy.  For example- checkpoint inhibitor given to pts that don’t recognize the tumors as foreign would have no benefits.  The    antisense platform has the potential of replacing small molecules and mAbs as it is a single platform with abundance of clinical safety data and requiring minimum testing for backbone toxicity- much the same way mAb was so attractive as a platform. This has allowed for rapid drug development such as Milasen-  developed from lab to patient in less than year. FDA has approved many antisense drugs recently including: Fomivirsinen, Macugen, Mipomersen, Nusinersen/Spinraza, Exondys, Luxturna, Inotersen, and Patisiran.  One especially high profile early failure is Oblimersen (Genesense, Genta). Poor management of Oblimersen tainted the field especially PS DNA backbone primarily because clinical trials proceeded for more than a decade including multiple phase III trials- despite marginal efficacy data due to wrong target.

Biography:

Vuong Trieu, Ph.D. is the founder and chairman of Oncotelic and was appointed to the Company’s Board and to serve as Chairman of the Board and CEO of Mateon in connection with the Merger with Oncotelic. Dr. Trieu is an expert is drug repositioning with several high profile successes including Abraxane and Cynviloq- both are billion dollar drugs. He is leading Mateon effort to become the next generation pharmaceutical by leveraging AI data analytics to create a high value pipeline. You don’t know what you don’t know- but there is no excuse for not knowing.